OPKO Health, Inc. Deferred State and Local Income Tax Expense (Benefit)
OPKO Health, Inc. (OPK) reported Deferred State and Local Income Tax Expense (Benefit) of $63.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2026-02-26
- OPKO Health, Inc. deferred state and local income tax expense (benefit) for fiscal 2025 was $63.00K, a 98.13% decline from fiscal 2024.
- OPKO Health, Inc. deferred state and local income tax expense (benefit) for fiscal 2024 was $3.38M.
- OPKO Health, Inc. deferred state and local income tax expense (benefit) for fiscal 2023 was -$298.00K.
- OPKO Health, Inc. deferred state and local income tax expense (benefit) for fiscal 2022 was -$12.08M.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month | Deferred State and Local Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $63.00K 10-K · filed 2026-02-26 | |
| 2024-12-31 | $3.38M 10-K · filed 2026-02-26 | |
| 2023-12-31 | -$298.00K 10-K · filed 2026-02-26 | |
| 2022-12-31 | -$12.08M 10-K · filed 2025-03-03 | |
| 2021-12-31 | -$1.28M 10-K · filed 2024-03-01 | |
| 2020-12-31 | -$933.00K 10-K · filed 2023-02-27 | |
| 2019-12-31 | -$125.00K 10-K · filed 2022-03-01 | |
| 2018-12-31 | -$5.67M 10-K · filed 2021-02-18 | |
| 2017-12-31 | $2.74M 10-K · filed 2020-03-02 | |
| 2016-12-31 | -$10.66M 10-K · filed 2019-03-01 | |
| 2015-12-31 | -$12.33M 8-K · filed 2019-01-29 | |
| 2014-12-31 | $167.00K 10-K · filed 2017-03-01 | |
| 2013-12-31 | $104.00K 10-K · filed 2016-02-29 | |
| 2012-12-31 | -$1.04M 10-K · filed 2015-02-27 | $1.04M 10-K · filed 2013-03-18 |
| 2011-12-31 | -$1.22M 10-K · filed 2014-03-03 | $1.22M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |